Literature DB >> 27660511

Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension.

Peter M Hickey1,2, Alfred A R Thompson1,2, Athanasios Charalampopoulos2, Charles A Elliot2, Neil Hamilton2, David G Kiely2, Allan Lawrie1, Ian Sabroe1,2, Robin Condliffe3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27660511     DOI： 10.1183/13993003.01004-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  9 in total

1.  Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Authors:  Marie-Camille Chaumais; Caroline O'Connell; Laurent Savale; Christophe Guignabert; Frédéric Perros; Xavier Jaïs; Olivier Sitbon; Marc Humbert; David Montani
Journal:  Int J Clin Pharm       Date:  2018-08-13

2.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

3.  iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension.

Authors:  Mingxia Gu; Michele Donato; Minzhe Guo; Neil Wary; Yifei Miao; Shuai Mao; Toshie Saito; Shoichiro Otsuki; Lingli Wang; Rebecca L Harper; Silin Sa; Purvesh Khatri; Marlene Rabinovitch
Journal:  Sci Transl Med       Date:  2021-05-05       Impact factor: 17.956

4.  A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.

Authors:  Karan Seegobin; Amit Babbar; Jason Ferreira; Brittany Lyons; James Cury; Vandana Seeram
Journal:  Pulm Circ       Date:  2017-10-24       Impact factor: 3.017

5.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 6.  A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.

Authors:  Zahra Nekoukar; Minoo Moghimi; Ebrahim Salehifar
Journal:  Blood Res       Date:  2021-12-31

7.  Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase.

Authors:  Ibuki Takatsuka; Hiroya Hirata; Takumi Takahashi; Satoshi Dohtan; Shinichiro Oka; Nami Sakamoto; Masamitsu Takaba; Miwa Adachi; Tomonari Takemura; Yasuyuki Nagata; Takaaki Ono
Journal:  Leuk Res Rep       Date:  2022-04-19

Review 8.  Differentiating pulmonary hypertension associated with protein kinase inhibitors.

Authors:  Joshua A Jacobs; Eiman Jahangir; John J Ryan
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886

9.  Dasatinib-induced Pulmonary Hypertension.

Authors:  Yudai Tamura; Yuichi Tamura
Journal:  Intern Med       Date:  2022-02-01       Impact factor: 1.282
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.